Remy Sukhija - 16 Jan 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Chief Commercial Officer
Issuer ticker: MDGL
Reported as of: 16 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jan 2023, 19:00:34 UTC
Prior SEC filing: 28 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Brian J. Lynch**

Filing notes and source

Key filing fact

Remy Sukhija filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 18 Jan 2023.

Key facts

This page summarizes Remy Sukhija's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jan 2023, 19:00.

Change

Previous filing in this sequence was filed on 28 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Award

Transaction value: $0
Shares: +15,001
Change %
Price: $0.000000
Shares after: 15,001
Date: 16 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.

SEC remarks

** As attorney-in-fact for Reporting Person